AbstractObjectiveEnrichment of circulating trophoblasts (CTs) from maternal blood at week 11–13 of gestation, using laminar microscale vortices, and evaluation of the performance of the VTX‐1 Liquid Biopsy System in terms of CT recovery and purity.MethodEight mililiter of blood was collected from 15 pregnant women and processed with the VTX‐1 Liquid Biopsy System. Y‐chromosome specific quantitative PCR was performed to estimate the number of enriched male CTs. To evaluate the VTX‐1 performance, the target cell recovery was characterized by spiking experiments with a trophoblast cell line. Furthermore, the total quantity of DNA after enrichment was used to calculate the number of retained maternal cells.ResultsSuccessful recovery of male CTs was established in 7 out of 10 first trimester samples from pregnant women carrying a male fetus. The number of CTs, recovered from 8 ml of blood, was estimated between two and six. Spiking experiments resulted in a CT recovery of ±35 % with ±1524 retained maternal blood cells.ConclusionCTs can be enriched from maternal blood with high purity, using laminar microscale vortices, starting from 8 ml of blood.

2018-02-01·SLAS Technology4区 · 医学

Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System

4区 · 医学

Article

作者: Lemaire, Clementine A ; Dimmick, Adam M ; Jeffrey, Stefanie S ; Liu, Sean Z ; Kochersperger, Michael L ; Vuppalapaty, Meghah ; Chiu, Michael W ; Wilkerson, Charles L ; Hengstler, Stephan ; Barzanian, Nasim A ; Che, James ; Sollier-Christen, Elodie ; Crouse, Steve C ; Huang, Kuo-Wei ; Renier, Corinne ; Ramani, Vishnu C ; Englert, Robert F ; Carlo, Dino Di

Tumor tissue biopsies are invasive, costly, and collect a limited cell population not completely reflective of patient cancer cell diversity. Circulating tumor cells (CTCs) can be isolated from a simple blood draw and may be representative of the diverse biology from multiple tumor sites. The VTX-1 Liquid Biopsy System was designed to automate the isolation of clinically relevant CTC populations, making the CTCs available for easy analysis. We present here the transition from a cutting-edge microfluidic innovation in the lab to a commercial, automated system for isolating CTCs directly from whole blood. As the technology evolved into a commercial system, flexible polydimethylsiloxane microfluidic chips were replaced by rigid poly(methyl methacrylate) chips for a 2.2-fold increase in cell recovery. Automating the fluidic processing with the VTX-1 further improved cancer cell recovery by nearly 1.4-fold, with a 2.8-fold decrease in contaminating white blood cells and overall improved reproducibility. Two isolation protocols were optimized that favor either the cancer cell recovery (up to 71.6% recovery) or sample purity (≤100 white blood cells/mL). The VTX-1's performance was further tested with three different spiked breast or lung cancer cell lines, with 69.0% to 79.5% cell recovery. Finally, several cancer research applications are presented using the commercial VTX-1 system.

项与 VTX-001 (Venn Therapeutics) 相关的新闻（医药）

2022-05-20

·vectorytx.com

VectorY presents 2 posters on the pre-clinical development of VTx-001 and VTx-002 at the American Society of Gene and Cell Therapy Congress 2022 Annual Meeting, May 16-19 in Washington, D.C.

Poster #1: VTx-001: VecTabs target Oxidized Phosphatidylcholine for Treating Amyotrophic Lateral Sclerosis (Pasteuning, S et al) Poster #2: VTx-002: VecTabs reduce TDP-43 Pathological Aggregates for Treating Amyotrophic Lateral Sclerosis (Pos, W et al)

基因疗法细胞疗法ASCO会议

100 项与 VTX-001 (Venn Therapeutics) 相关的药物交易

登录后查看更多信息